Patterns of Human Papillomavirus Types in Multiple Infections: An Analysis in Women and Men of the High Throughput Human Papillomavirus Monitoring Study

Vaccarella, Salvatore; Söderlund Strand, Anna; Franceschi, Silvia; Plummer, Martyn; Dillner, Joakim

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0071617

2013

Link to publication

Citation for published version (APA):
Vaccarella, S., Söderlund Strand, A., Franceschi, S., Plummer, M., & Dillner, J. (2013). Patterns of Human Papillomavirus Types in Multiple Infections: An Analysis in Women and Men of the High Throughput Human Papillomavirus Monitoring Study. PLoS ONE, 8(8), [e71617]. https://doi.org/10.1371/journal.pone.0071617

Total number of authors:
5

General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Patterns of Human Papillomavirus Types in Multiple Infections: An Analysis in Women and Men of the High Throughput Human Papillomavirus Monitoring Study

Salvatore Vaccarella¹*, Anna Söderlund-Strand², Silvia Franceschi¹, Martyn Plummer¹, Joakim Dillner¹,²,³

¹International Agency for Research on Cancer, Lyon, France, ²Department of Clinical Microbiology, Skåne University Hospital, Malmö, Sweden, ³Departments of Laboratory Medicine, Medical Epidemiology and Biostatistics, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden

Abstract

Background: To evaluate the pattern of co-infection of human papillomavirus (HPV) types in both sexes in Sweden.

Methods: Cell samples from genital swabs, first-void urine, and genital swabs immersed in first-void urine were collected in the present cross-sectional High Throughput HPV Monitoring study. Overall, 31,717 samples from women and 9,949 from men (mean age 25) were tested for 16 HPV types using mass spectrometry. Multilevel logistic regression was used to estimate the expected number of multiple infections with specific HPV types, adjusted for age, type of sample, and accounting for correlations between HPV types due to unobserved risk factors using sample-level random effects. Bonferroni correction was used to allow for multiple comparisons (120).

Results: Observed-to-expected ratio for any multiple infections was slightly above unity in both sexes, but, for most 2-type combinations, there was no evidence of significant departure from expected numbers. HPV6/18 was found more often and HPV51/68 and 6/68 less often than expected. However, HPV68 tended to be generally underrepresented in co-infections, suggesting a sub-optimal performance of our testing method for this HPV type.

Conclusions: We found no evidence for positive or negative clustering between HPV types included in the current prophylactic vaccines and other untargeted oncogenic types, in either sex.

Citation: Vaccarella S, Söderlund-Strand A, Franceschi S, Plummer M, Dillner J (2013) Patterns of Human Papillomavirus Types in Multiple Infections: An Analysis in Women and Men of the High Throughput Human Papillomavirus Monitoring Study. PLoS ONE 8(8): e71617. doi:10.1371/journal.pone.0071617

Editor: Silvia de Sanjose, The Catalan Institute of Oncology (ICO), Spain

Received March 16, 2013; Accepted July 1, 2013; Published August 19, 2013

Copyright: © 2013 Vaccarella et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by research grants from Osterlund Foundation; Region Skåne Clinical Research Funds; and by a grant from the Bill & Melinda Gates Foundation (grant number OPP1053353). The HT-HPV study was supported by Sanofi Pasteur MSD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The HT-HPV study was supported by Sanofi Pasteur MSD. Dr J. Dillner has acted as consultant for and received research grants from Merck/Sanofi Pasteur MSD. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

* E-mail: vaccarella@iarc.fr

Introduction

Persistent infection with human papillomavirus (HPV), a common sexually transmitted infection, is considered a necessary cause of cervical cancer and is also associated with other anogenital cancers in men and women [1]. Genital infection with multiple HPV types is commonly found in women [2–12] and men [13–17].

Current prophylactic HPV vaccines target the two most oncogenic types, HPV16 and 18, and one of the two vaccines also targets two non-oncogenic types, HPV6 and 11. A possibility exists that the decrease of certain HPV types through vaccination could lead to a shift in the distribution of HPV genotypes, with an increase (replacement) or decrease (on account of cross-protection [18]) in the prevalence of non-targeted HPV types in the population. This issue can only be fully answered by prospective studies of vaccinated populations. However, some information on whether such changes are likely or not can be gained by studying infections with multiple HPV types, and using a statistical model to determine whether the prevalence of multiple infections can be explained entirely by their shared sexual transmission and common risk factors.

Previous analyses on the frequency of individual HPV types in co-infections with multiple types suggest that they do not tend to cluster together selectively in either sex [2,3,7,0,11,16,19]. Some studies reported that co-infections with certain HPV types occurred more often than what was expected, but this was explained by diagnostic artefacts due to limitations of the HPV detection method used [2,16]. Overall, multiple co-infections show no specific pattern by HPV type. However, a full evaluation of the analysis of 2-type associations between all the different HPV types requires a large number of infections and should preferably include men and women. In the present analysis, therefore, we evaluated the patterns of HPV types in co-infections in women and men in a large study, the High Throughput HPV Monitoring (HT-HPV) study.
Methods

Study Population

The HT-HPV study was a survey of HPV prevalence among young sexually active women and men in Southern Sweden. The aim of the HT-HPV study was to establish baseline data to monitor the input of HPV vaccination. The study was based on participants in the Chlamydia trachomatis testing programme, which mainly recruited participants from youth clinics for sexual health counselling; gynecology clinics/maternal care units (women only); venereology/urology clinics; and primary care units. Samples collected for Chlamydia trachomatis testing were also analyzed for HPV DNA. All samples were anonymized and age and sex are the only information available for study participants. The Regional Ethical Review Board for Southern Sweden approved the study and decided that informed consent for HPV testing was not required, since samples were anonymized. We cannot, therefore, identify which samples are repeat tests on the same individuals and the total number of participants is not known exactly. Although the study size is reported in terms of samples, not individuals, it is estimated that the number of unique individuals is 78% of the number of samples [20].

Overall, 44,146 urine and swab samples were collected (33,137 from women and 11,009 from men) between March and October 2008 using the multi-Collect Specimen Collection Kit and following the manufacturer’s instructions (Abbott Molecular, Illinois, USA). The present analysis is restricted to urogenital samples, with samples taken from women and 11,009 from men) between March and October

| Table 1. Observed-to-expected ratio of multiple human papillomavirus infections, according to two models, in women (a) and men (b), Sweden. |
|---|
| **a)** | **Basic model** | **Full model** |
| **No of HPV types** | O | % | E\(^a\) | O/E (95% CI)\(^a\) | E\(^b\) | O/E (95% CI)\(^b\) |
| 0 | 19,506 | 61.5 | 17,179.2 | 1.14 (1.13–1.14) | 19,196.8 | 1.02 (1.01–1.02) |
| 1 | 7,091 | 22.4 | 10,161.8 | 0.70 (0.69–0.70) | 7,855.5 | 0.90 (0.89–0.91) |
| 2 | 3,246 | 10.2 | 3,415.6 | 0.95 (0.93–0.97) | 2,892.9 | 1.12 (1.11–1.14) |
| ≥3 | 1,874 | 5.9 | 960.5 | 1.95 (1.88–2.03) | 1,771.7 | 1.06 (1.03–1.09) |
| **b)** | **Basic model** | **Full model** |
| **No of HPV types** | O | % | E\(^a\) | O/E (95% CI)\(^a\) | E\(^b\) | O/E (95% CI)\(^b\) |
| 0 | 8,845 | 88.9 | 8,612.6 | 1.03 (1.02–1.03) | 8,837.4 | 1.00 (0.99–1.01) |
| 1 | 859 | 8.6 | 1,241.2 | 0.69 (0.66–0.73) | 886.7 | 0.97 (0.92–1.03) |
| ≥2 | 245 | 2.5 | 95.2 | 2.58 (2.34–2.85) | 224.9 | 1.09 (1.00–1.19) |

HPV: human papillomavirus; O: observed; E: expected; CI: credible interval.

\(^a\)Adjusted for age, type of sample, and type-specific HPV prevalence.

\(^b\)As\(^a\) plus sample random effects.

doi:10.1371/journal.pone.0071617.t001

HPV Testing and Genotyping

DNA was extracted for Chlamydia trachomatis testing using the Abbott m2000sp system according to the manufacturer’s instructions (Abbott Molecular, Illinois, USA), the residual DNA was tested for HPV6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, using polymerase chain reaction (PCR) followed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MS), as previously described [20]. Briefly, the MS method involves a consensus PCR reaction using the MGP primer system [21] followed by a mass extension (ME) reaction with a single ME primer of distinct mass that is specific for each HPV genotype. After completion of the ME reaction, unextended primers demonstrate the absence and extended primers the presence and identity of each specific genotype. In each MS run, the proficiency panel consisting of 43 samples with HPV plasmid dilutions in defined amounts (traceable to the International Standard for HPV DNA) was re-tested and negative controls (human DNA in Tris-EDTA buffer) included. The MS method was favourably assessed in the 2008 [22] and in the 2010 WHO Global HPV LabNet HPV DNA typing proficiency panel [23].

Among all types detected by MS-analysis, HPV68 was the type with the lowest probability to be detected (91%) when samples contained 200 copies per reaction. The detection probability was 26% when HPV68 was present in low copy numbers, i.e., 20 copies/reaction or in presence of other HPV types (detection probability = 17%) (JD, personal communication). Furthermore, the ME primer for HPV68 showed some cross-reactivity with HPV70 and consequently HPV68-positive samples were retested by using a Luminex-based detection with probes for HPV68A (GenBank accession number DQ0800079), HPV68B (GenBank accession number M73258 for the original sequence ME180), and HPV70 for confirmation of the results [20].

Statistical Analysis

The present analysis focused on 16 HPV types, including all 13 oncogenic types, i.e., HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 [24] and two low-risk types, HPV6 and 11, targeted by one of the two currently available HPV vaccines. A logistic regression model was fitted with type-specific HPV positivity as an outcome, controlling for age (<20, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, ≥50 years), type of sample (urine only, genital swabs combined to urine, genital swabs only), and type-specific HPV prevalence, as previously described [2]. As the data have a hierarchical structure, with HPV infections nested within samples, multilevel models were used, with sample-level random effects. In this context, a random effect is an unobserved quantity that varies between samples and allows different levels of risk for prevalent HPV infection given the same observable risk factors. Random effects account for the fact that type-specific HPV measurements between samples and allows different levels of risk for prevalent HPV infection given the same observable risk factors. Random effects account for the fact that type-specific HPV measurements
Figure 1. Type-specific human papillomavirus prevalence in samples from women (a) and men (b), Sweden.
doi:10.1371/journal.pone.0071617.g001
Multiple HPV Infections in Sweden

Table 2. Human papillomavirus types showing significant excess or deficit in 2-type co-infections, Sweden.

| Level of significance | Co-infection with HPV types | Female samples (N = 31,717) | Male samples (N = 9,949) |
|-----------------------|-----------------------------|-----------------------------|--------------------------|
|                       | O                           | E*                         | O/E*                     | P-value | O                           | E*                         | O/E*                     | P-value |
| <0.0004               | 6/18                        | 198                        | 146.4                    | 1.35    | 0.00028                     | 16                        | 11.4                     | 1.42    | 0.30214 |
| (Bonferroni)          | 51/68                       | 15                         | 36.7                     | 0.41    | 0.00300                     | 0                         | 0.9                      | 0       | 0.77396 |
|                       | 6/68                        | 7                          | 26.0                     | 0.27    | 0.00010                     | 0                         | 0.9                      | 0       | 0.82234 |
| <0.01                 | 56/66                       | 190                        | 143.5                    | 1.332   | 0.00050                     | 6                         | 4.7                      | 1.31    | 0.68458 |
|                       | 18/35                       | 34                         | 60.8                     | 0.56    | 0.00054                     | 1                         | 1.7                      | 0.63    | 0.93284 |
|                       | 35/66                       | 34                         | 60.5                     | 0.56    | 0.00050                     | 1                         | 1.6                      | 0.65    | 0.96466 |
|                       | 6/58                        | 49                         | 73.8                     | 0.67    | 0.00414                     | 3                         | 4.4                      | 0.70    | 0.74580 |
|                       | 33/56                       | 74                         | 69.7                     | 1.06    | 0.65868                     | 7                         | 1.9                      | 3.86    | 0.00810 |
|                       | 16/59                       | 164                        | 172.0                    | 0.95    | 0.60632                     | 13                        | 3.6                      | 3.72    | 0.00076 |

N: number; HPV: human papillomavirus; O: observed; E: expected.

*Two thresholds of significance are considered: one based on the Bonferroni method, i.e., 0.0004, and 0.01;
**Results are displayed if statistically significant in either women or men;
*Urine, urine+genital or vagina, cervix, cervix+urethra, urethra;
*Urine, urine+genital, urethra;
+As estimated by the Full model.

doi:10.1371/journal.pone.0071617.t002

(1) (observed counts of co-infections per sample) and the model (expected counts of co-infections per sample) were assessed by posterior predictive two-sided p-values and measured by an observed-to-expected (O/E) ratio for each HPV co-infection [25]. All possible two-type interactions between the 16 HPV types were assessed and, therefore, 120 (16 x 15/2) statistical comparisons were generated for each sex. To minimize errors due to multiple comparisons, the Bonferroni correction was used to assess statistical significance. With 120 multiple comparisons for each sex, Bonferroni corrected p-value threshold for 2-type co-infections is 0.05/120 = 0.0004. For comparability with previous studies in which less conservative approaches had been used, we additionally reported associations that were significant by a p-value threshold of 0.01.

Results

A total of 31,717 samples from women (mean age = 25.1 years, interquartile interval: 19–29 years) and 9,949 from men (25.3 years, interquartile interval: 20–29 years) were included in the present analysis. Type-specific prevalence for women and men was described in detail elsewhere [20]. Briefly, 38.5% of samples from women and 11.1% from men were HPV-positive in the HT-HPV study. In both sexes, HPV positivity was lower in first-void urine samples (27.2% in women; 10.5% in men) compared to combined samples with genital swabs immersed in first-void urine (44.9% in women; 22.2% in men) and to genital swab samples (43.0% in women; 21.3% in men) [20].

Table 1 shows the O/E ratios of women (1a) and men (1b) with single and multiple HPV infections. Multiple infections were detected in 41.9% of the 12,211 HPV-positive women and in 22.2% of the 1,104 HPV-positive men. The Basic model included only age, type of sample, and specific HPV prevalence as covariates. The Full model included, in addition to the covariates of the Basic model, sample-random effects. In the Basic model among women, there were fewer double infections (O/E ratio 0.95, 95% CI: 0.93–0.97), but more multiple infections with ≥3 HPV types than expected (O/E ratio 1.95, 95% CI: 1.88–2.03). In men, the O/E ratio for ≥2 HPV types was 2.58 (95% CI: 2.34–2.85). In the Full model, the O/E ratio among women was 1.12 (95% CI: 1.11–1.14) for 2-types and it decreased to 1.06 (95% CI: 1.03–1.09) for ≥3-type co-infections. Among men, the O/E ratio for ≥2-type co-infections accordingly to the Full model decreased to 1.09 (95% CI: 1.00–1.19).

In appendix (Table S1), we present analyses for women stratified according to the type of sample. With the Basic model, the O/E ratio for infections with ≥3 HPV types was greater in urine samples only (3.04, 95% CI: 2.80–3.29) than in urine plus genital samples (1.79, 95% CI: 1.72–1.86). With the Full model, however, the two O/E ratios were similar for the two types of samples (1.05, 95% CI: 0.99–1.12; and 1.06, 95% CI: 1.02–1.09, respectively). In women, the proportion of HPV types involved in multiple infections ranged between 58.4% for HPV11 to 70.0% for HPV33 (Figure 1A). In men, the proportion of HPV types involved in multiple infections ranged between 30.0% for HPV58 to 62.9% for HPV59 (Figure 1B).

Table 2 shows the significant associations observed between 2-type combinations of HPV types in each sex, under the Full model. Only 3 associations reached the Bonferroni level of significance in women: HPV6/18 was found more often and HPV59 (Figure 1B).

In women, the proportion of HPV types involved in multiple infections ranged between 58.4% for HPV11 to 70.0% for HPV33 (Figure 1A). In men, the proportion of HPV types involved in multiple infections ranged between 30.0% for HPV58 to 62.9% for HPV59 (Figure 1B).

Figure 2 shows the location for all 2-type co-infections of 16 HPV types across the diagonal drawn between the axis of the expected (horizontal) and observed (vertical) frequency in women. Plus signs represent HPV pairs. HPV pairs located in the upper triangle indicate positive clustering, while those located in the lower triangle represent negative clustering between the HPV types involved. As shown in Table 2, HPV6/18 was found significantly more often than expected while HPV6/68 and HPV51/68 were observed significantly less often than expected in 2-type co-infections. However, the majority of co-infections...
involving HPV68 also fell below the diagonal although the corresponding O/E ratios were not significantly different from unity (Figure 2, small bottom-right box). None of the other HPV types, including HPV6 (small top-left box), showed the same behaviour. Figure 3 reproduces the approach of Figure 2 for men and does not show any significant excess or deficit of 2-type infections.

**Discussion**

Our large cross-sectional study of patterns of HPV types in multiple infections shows that, although HPV types often cluster together due to the common route of transmission, 2-type co-infections tend to occur at random in both sexes.

Our findings are thus consistent with previous studies from different areas of the world that showed, in both sexes, high frequency of multiple HPV infections but no significant excess or deficit of any 2-type combination [2,3,5–7,9,10,16,17]. In some instances, significant clusters were observed but they were attributable to technical problems. For instance, an analysis of the International Agency for Research on Cancer HPV Prevalence Surveys that used GP5+/6+ PCR assays to detect HPV, showed an excess of co-infections with HPV33/58, 18/45, 33/35, and 31/35 that was attributable to the cross-hybridization of highly homologous HPV types using enzyme immunoassay for genotyping [2]. Another analysis of the HPV in Men study found an apparent clustering of HPV52 with HPV35 or 58, which was due to the inability of the Roche Linear Array test to measure directly HPV52 positivity. HPV52 had, therefore, to be evaluated by subtraction using a mixed probe that also included HPV33, 35 and 58 [16].

The evaluation of HPV type patterns in multiple infections requires large studies on account of the need for multiple testing. Adequate statistical power is especially important when assessing the significance level of negative associations that involve rare HPV types. In the present study, there was no evidence of systematic clustering for most HPV types. Two of the three statistically significant associations in women involved HPV68, with either HPV6 or 51. However, HPV68 revealed a general
tendency to be underrepresented in 2-type infections, although in most instances negative associations did not reach any of the two chosen levels of significance. The same behaviour was not observed for any other HPV type, including HPV6 that was also involved in two significant clusters: one more frequent and the other less frequent than expected. The most likely explanation of HPV68 pattern in multiple infections is a diagnostic artefact, on account of a less-than-optimal performance of the MS diagnostic method to detect HPV68, particularly where HPV68 is present in low copy numbers and in the presence of other HPV types.

Confirmatory testing of HPV68-positive samples with Luminex was performed to overcome cross-reactivity of HPV68 with 70 in the MS method. This step had the potential to improve the specificity but not the sensitivity of HPV68 testing in our study. Restriction to the original MS-based testing data did not make any difference (data not shown).

The excess of co-infections involving HPV6 and 18, two HPV types that are both targeted by current vaccines and that belong to different alpha species (alpha species 10 and 7, respectively), has no clear explanation, but we cannot exclude that it could be due to an extreme play of chance. An excess of co-infections, also emerged for genetically similar types HPV56 and 66, both belonging to alpha-6 species, but it was not statistically significant after Bonferroni correction.

Overall HPV prevalence in our study was higher in women (38.5%) compared to men (11.1%) [20]. The majority (>90%) of the samples from men in this study were urine only samples, whereas a combination sample with both genital swab and urine was most commonly used for women. Urine samples have a lower sensitivity to detect HPV than gold-standards (cervico-vaginal or penile swabs) and the problem is more severe in men (sensitivity estimates range between 28–56%) than in women (sensitivity estimates range between 84–91%) [26,27]. The lower sensitivity in men can, at least partly, explain lower HPV prevalences compared to women and implies lower statistical power to detect significant HPV type clusters. Different sexual behaviours and, hence, different HPV prevalence in female and male participants to the Chlamydia trachomatis testing programme cannot be ruled out.

HPV testing in urine is affected by methods of collection, storage, DNA extraction, and the conservation medium used to avoid DNA degradation [28]. In our study, we used a validated protocol [20] and a commercial kit that included a buffer to stabilize DNA. Samples in which swabs were added to urine samples showed a similar HPV prevalence as those from genital swabs in both sexes [20], implying that sensitivity to detect HPV in genital swabs is not reduced after immersion in urine.

Genital swabs included in our study were collected in large majority from the cervix in women and the urethra in men and, therefore, our findings in swabs are likely to reflect the patterns of HPV co-infections in these genital sites. The comparison of findings in samples from women that included genital swabs with urine samples showed that, despite lower HPV-positivity in urine, the patterns of multiple infections with HPV types were consistent in the two sample types.

Information on sexual behaviour was not available in the HT-HPV study. Therefore, the inclusion of sample-level random effects was particularly useful in order to allow for unobservable risk factors common to all HPV types. Sample-level random
effects, in fact, reduced substantially the O/E ratio for multiple HPV infections in both sexes. Sample-level random effects keep into account unobserved risk factors but do not allow to distinguish the effect of sexual behaviour from that of other risk factors, e.g., immunological susceptibility. The small excess of multiple HPV infections, present even after the inclusion of random effects, has also been observed in previous studies in both genders [2,10,11,16]. We cannot exclude that it could be due to diagnostic artifacts or, alternatively, to some weak residual tendency of specific type combinations to cluster together that is not detectable unless we aggregate overall 2-type combinations.

A further limitation of the present study is that a proportion of samples, estimated to be around 22%, were repeat tests on the same individuals. As samples were anonymized, we could not identify repeat samples and allow for correlated measures, but we assumed that they were randomly distributed across subjects. Should that not be the case, we, however, expect that the use of random effects will prevent point estimates of O/E ratios from being substantially affected by the presence of repeated samples. Credible intervals, however, may be smaller than in the case of independent tests but this limitation should, if anything, lead to a larger number of significantly increased 2-type co-infections.

In conclusion, understanding whether certain HPV types have a tendency to cluster together in unvaccinated populations is important to evaluate the potential for type-replacement and cross-protection in HPV vaccine recipients and to understand better the natural history of the infection. Our study confirms in both sexes the lack of evidence of negative and positive clustering between types included in the current prophylactic HPV vaccines and other untargeted oncogenic types. In the present analysis, HPV6/68 and HPV31/68 were observed significantly less often than expected, but that was part of a general tendency of HPV68 to be underrepresented in combination with all other types. Lack of multiple infections involving HPV68 was likely to be due to a less-than-optimal performance of the MS primer for this type. The elimination of some HPV types by vaccination is thus unlikely to have any major effects on the occurrence of other HPV types.

Supporting Information

Table S1 Observed-to-expected ratio of multiple human papillomavirus infections, according to two models: in urine samples only (a); genital swabs only and genital swabs immersed in first-void urine (b), in women, Sweden. HPV: human papillomavirus; O: observed; E: expected; CI: credible interval. *Controlling for age and type-specific HPV prevalence; †As a plus sample random effects.

Acknowledgments

The work reported was undertaken while Dr. J. Dillner was hosted as Senior Visiting Scientist by the International Agency for Research on Cancer.

Author Contributions

Conceived and designed the experiments: SV SF JD. Analyzed the data: SV MP. Contributed reagents/materials/analysis tools: ASS. Wrote the paper: SV JD SF.

References

1. IARC (2007) Monographs on the Evaluation of carcinogenic risks to Humans Volume 90: Human Papillomavirus. Lyon: International Agency for Research on Cancer.
2. Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, et al. (2010) Concurrent Infection with Multiple Human Papillomavirus Types: Pooled Analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 19: 503–510.
3. Thomas KK, Hughes JP, Kuppers JM, Kiviat NB, Lee SK, et al. (2000) Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 182: 1197–1202.
4. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, et al. (2001) A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 183: 8–13.
5. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, et al. (2001) Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 184: 1508–1517.
6. Chaturvedi AK, Myers L, Hammons AF, Clark RA, Dunlap K, et al. (2005) Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev 14: 2439–2443.
7. Mendez F, Munoz N, Posso H, Molano M, Moreno V, et al. (2005) Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 192: 1136–1145.
8. Chaturvedi A, Katki H, Hildesheim A, Rodriguez AC, Quint W, et al. (2011) Human Papillomavirus infection with multiple types: Pattern of co-infection and risk of cervical disease. J Infect Dis 203: 910–920.
9. Vaccarella S, Franceschi S, Herrero R, Munoz N, Snijders PJF, et al. (2006) Sexual behavior, condom use and HPV: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 15: 328–333.
10. Carnezi F, Roqueiro G, Gilło-Toz A, de Marco L, Del Mistro A, et al. (2012) Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. Eur J Cancer 48: 1633–1637.
11. Vaccarella S, Franceschi S, Herrero R, Schiffman M, Rodriguez AC, et al. (2011) Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. J Infect Dis 204: 385–390.
12. Goldman B, Rebolj M, Rygaard C, Peisler S, Egejed DM, et al. (2013) Patterns of cervical coinfection with multiple human papillomavirus types in a screening population in Denmark. Vaccine 31: 1604–1609.
13. Vaccarella S, Lazzcano-Ponce E, Castro-Garduño JA, Cruz-Valdés A, Díaz V, et al. (2006) Prevalence and determinants of human papillomavirus infection in men attending vasectomy clinics in Mexico. Int J Cancer 119: 1934–1939.
14. Lajous M, Mueller N, Cruz-Valdés A, Aguilar LV, Franceschi S, et al. (2005) Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 14: 1710–1716.
15. Nilson CM, Harris RB, Flores R, Abrahamsen M, Papenfuss MR, et al. (2009) Multiple-type human papillomavirus infection in male anogenital sites: prevalence and associated factors. Cancer Epidemiol Biomarkers Prev 18: 1077–1083.
16. Vaccarella S, Plummer M, Franceschi S, Gravitt P, Papenfuss M, et al. (2011) Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study. J Infect Dis 204: 1500–1504.
17. Rositch AF, Poole C, Hudgens MG, Agot K, Nyagaya E, et al. (2012) Multiple human papillomavirus infections and type competition in men. J Infect Dis 205: 72–81.
18. Wheeler CM, Castlesque X, Garland SM, Szarewski A, Paavonen J, et al. (2012) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precursor caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13: 100–110.
19. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, et al. (1999) Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180: 1415–1423.
20. Soderlund-Strand A, Dillner J. (2013) High-throughput monitoring of human papillomavirus type distribution. Cancer Epidemiol Biomarkers Prev 22: 242–250.
21. Soderlund-Strand A, Carlson J, Dillner J. (2009) Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol 47: 541–546.
22. Ekldin C, Zhou T, Dillner J. (2010) Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 48: 4147–4155.
23. Ekldin C, Forslund G, Walfin KL, Zhou T, and Dillner J. (2012) The 2010 global proficiency study of human papillomavirus genotyping in virology. J Clin Microbiol 50: 2298–91.
24. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, et al. (2009) A review of human carcinogenicity Part B: biological agents. Lancet Oncol 10: 321–322.
25. Gillman A, Carlin JB, Stern HS, Rubin DB. (2004) Bayesian Data Analyses, Second Edition. Boca Raton: CRC Press LLC. 689 p.
26. Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscornet L, et al. (2011) Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol 83: 1744–1751.
27. Cuschieri K, Nandwani R, McGough P, Cook F, Hogg L, et al. (2011) Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. J Med Virol 83: 1983–1987.
28. Vorsters A, Micalessi I, Bilcke J, Ieven M, Bogers J, et al. (2012) Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol Infect Dis 31: 627–640.